Pharma BD Deal Intelligence
GSK's $10.6B all-cash tender for Nuvalent buys two late-stage, potentially best-in-class TKIs—zidesamtinib for ROS1+ and neladalkib for ALK+ NSCLC—both already under FDA review with 2026 action dates. It's a bet on near-term approvals rather than a pipeline gamble, though both assets still need to clear FDA review before GSK sees a return.
GSK boosts cancer pipeline with $11B Nuvalent buyout. GSK called it a multi-product deal 'consistent with our approach to acquire assets that have clinically…
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall. Investors remain cautious over the size of the acquisition and the regulatory risk…
Nuvalent surges 39% premarket as GSK acquires for $10.6B at a 40% premium. Its two potential blockbuster drugs are expected to contribute to profits starting…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
GSK agreed to acquire clinical-stage oncology company Nuvalent via an all-cash tender offer of $124.00 per share, ~$10.6 billion total (~$9.4 billion net of cash), announced June 9, 2026. The deal adds two late-stage, potential best-in-class next-generation selective tyrosine kinase inhibitors for non-small cell lung cancer: zidesamtinib (NVL-520, ROS1) and neladalkib (NVL-655, ALK). Both hold FDA Breakthrough Therapy and Orphan Drug designations and are under FDA review, with target action dates of 18 September 2026 (zidesamtinib) and 27 November 2026 (neladalkib). Expected to close in 2026.
Zidesamtinib NDA (ROS1+ NSCLC, TKI-pretreated) carries a PDUFA target date of September 18, 2026; neladalkib NDA (ALK+ NSCLC, TKI-pretreated) was granted Priority Review with a PDUFA date of November 27, 2026 (ALKOVE-1 data).
GSK agreed to acquire Nuvalent at $124.00 per share in cash (~$10.6B total, ~$9.4B net of cash), adding two potential best-in-class NSCLC TKIs ahead of their 2026 PDUFA dates.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Nuvalent, Inc. (this deal) | 2026 | $10.6B | 70 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
| GSK plc / Human Genome Sciences | 2012 | $3.6B | 70 |
← Browse all deals · How we score deals
More: 2026 deals · GSK plc deals · Oncology deals